PAOLA-1 : Randomized, Double-Blind, Phase III Trial of Olaparib vs. Placebo in Patients with Advanced FIGO Stage IIIB – IV High Grade Serous or Endometrioid Ovarian, Fallopian Tube, or Peritoneal Cancer treated with standard First-Line Treatment, Combining Platinum-Taxane Chemotherapy and Bevacizumab Concurrent with Chemotherapy and in Maintenance

Sponsor: ARCAGY Research (for GINECO)
Principal Investigator: Prof. Isabelle RAY-COQUARD
Centre Léon BERARD, Lyon, France

PAOLA-1 Study



Planned No. of patients: 762 (=612 +150) +24 in Japan

Current accrual: 682 (15/05/17)

PAOLA-1 Study: new statistical hypothesis

❖ New data on PARPi efficacy in maintenance have been recently disclosed in NOVA trial[5] and stressed the importance of the tumor homologous recombination deficiency (HRD) in the efficacy of PARPi in ovarian carcinoma.

❖As in the NOVA trial the magnitude of PARPi efficacy for patients with HRD negative tumors was found to be small, it is assumed that in the PAOLA-1 trial, the potential benefit of olaparib will be driven mainly by the BRCAm & HRD positive subset (representing approximately 55% of the total population).

❖Given these considerations, the planned sample size seems to be underpowered to detect a significant difference in ITT with an assumed control median PFS population.

❖ The new calculation has taken into account the expected different levels of benefit according to the patient subsets and they were applied in deriving an appropriate sample size.of 15.8 months and a HR of 0.75 in the ITT population, a total of 458 events would have the adequate power (> 80%) to show a statistically significant difference PFS1 between the 2 arms at a 2-sided alpha.

❖Interim analysis will be performed for efficacy after 229 events (50% PFS1).

❖The sample size has been **increased by 150 patients in Europe** (100 in the olaparib arm and 50 patients in the placebo arm) up to **762 patients** maintaining 60% maturity.

PAOLA-1 status (15/05/2017)

Accrual



Global recruitment





Randomizations per month



Expected end of recruitment July 2017